| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
11,450,000 |
| Market
Cap: |
8.14(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2893 - $1.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Monopar Therapeutics is a biopharmaceutical company focused on developing proprietary therapeutics for cancer patients. Co.'s compounds in development: Validive®, a Phase 2b/3 clinical stage, mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a Phase 1b clinical stage analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; MNPR-101, a preclinical stage uPAR-targeted antibody being developed as a radioimmunotherapeutic and companion diagnostic for cancers and COVID-19; and an early stage camsirubicin analog, MNPR-202, for various cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
16,053 |
| Total Buy Value |
$0 |
$0 |
$0 |
$49,659 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Brown Michael J |
Chief Executive Officer |
– • • |
2019-12-18 |
4 |
B |
$8.00 |
$1,000,000 |
D/D |
125,000 |
291,667 |
0.01 |
- |
|
| Leo Karl |
|
– – • |
2019-12-18 |
4 |
B |
$8.00 |
$2,510 |
D/D |
314 |
314 |
0.01 |
- |
|
| Leo Karl |
|
– – • |
2019-12-18 |
4 |
B |
$8.00 |
$1,250,000 |
I/I |
156,250 |
156,250 |
0.01 |
- |
|
| Tsuchimoto Kim R |
Chief Financial Officer |
• – – |
2019-12-18 |
4 |
B |
$8.00 |
$2,600 |
D/D |
325 |
325 |
0.01 |
- |
|
| Rioux Patrice |
Acting Chief Medical Officer |
– – – |
2019-11-26 |
4 |
OE |
$0.00 |
$109,998 |
D/D |
18,433 |
18,433 |
|
- |
|
155 Records found
|
|
Page 7 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.04 (5.19%) 
